A Look Ahead: Inotiv's Earnings Forecast
Inotiv (NASDAQ:NOTV) is gearing up to announce its quarterly earnings on Monday, 2026-02-09. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Inotiv will report an earnings per share (EPS) of $-0.42.
Inotiv bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Past Earnings Performance
During the last quarter, the company reported an EPS missed by $0.17, leading to a 6.53% drop in the share price on the subsequent day.
Here's a look at Inotiv's past performance and the resulting price change:
| Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| EPS Estimate | -0.08 | -0.15 | -0.23 | -0.42 |
| EPS Actual | -0.25 | -0.51 | -0.44 | -1.02 |
| Price Change % | -7.00 | -11.00 | 10.00 | -6.00 |
Market Performance of Inotiv's Stock
Shares of Inotiv were trading at $0.39 as of February 05. Over the last 52-week period, shares are down 88.47%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
Analysts' Perspectives on Inotiv
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Inotiv.
The consensus rating for Inotiv is Buy, derived from 1 analyst ratings. An average one-year price target of $3.0 implies a potential 669.23% upside.
Analyzing Ratings Among Peers
In this analysis, we delve into the analyst ratings and average 1-year price targets of Bionano Genomics and Quantum-Si, three key industry players, offering insights into their relative performance expectations and market positioning.
- Analysts currently favor an Buy trajectory for Bionano Genomics, with an average 1-year price target of $7.0, suggesting a potential 1694.87% upside.
- Analysts currently favor an Neutral trajectory for Quantum-Si, with an average 1-year price target of $1.5, suggesting a potential 284.62% upside.
Peer Metrics Summary
The peer analysis summary provides a snapshot of key metrics for Bionano Genomics and Quantum-Si, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Inotiv | Buy | 5.92% | $33.03M | -6.11% |
| Bionano Genomics | Buy | 21.31% | $3.37M | -17.87% |
| Quantum-Si | Neutral | -29.86% | $194K | -15.65% |
Key Takeaway:
Inotiv ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.
All You Need to Know About Inotiv
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Inotiv's Financial Performance
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Inotiv's remarkable performance in 3 months is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 5.92%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Inotiv's net margin is impressive, surpassing industry averages. With a net margin of -6.19%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Inotiv's ROE excels beyond industry benchmarks, reaching -6.11%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.12%, the company showcases effective utilization of assets.
Debt Management: Inotiv's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.38, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
To track all earnings releases for Inotiv visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.